Concentra Biosciences to Acquire IGM Biosciences for $1.247 per Share in Cash Plus Contingent Value Right.

IGM Biosciences has agreed to be acquired by Concentra Biosciences for $1.247 per share in cash, with shareholders receiving a contingent value right promising additional returns. The merger is expected to close in August 2025, subject to specific conditions. The deal highlights Concentra's interest in IGM's cash reserves while providing potential upside to shareholders contingent on asset sales.